罗格列酮药代动力学及临床应用研究进展

Advance in search for pharmacokinetics and clinical practice of rosiglitazone

罗格列酮是新型噻唑烷二酮类降糖药,通过激活过氧化物酶增生激活受体(PPARγ),改善肌肉、脂肪组织的胰岛素敏感性,控制血糖。罗格列酮还有潜在的心血管保护作用及改善胰岛β细胞的功能。本文综述了罗格列酮药代动力学及药物相互作用的研究进展。

Rosiglitazone is a member of the thiazolidinedione class,It can improve insulin sensitivity in muscle and adipose tissue and control hyperglycemia by activating peroxisome proliferator-activated receptor-γ(PPARγ).The drug may have the potential to protect cardiovascular system and improve pancreative β-cell function。Its analytical methods,pharmacokinetics,population pharmacokinetics,pharmacokinetics in special populations, pharmacokinetics of dosage regimens,interaction of pharmacokinetics are reviewed in this paper。